Type III Secretion Systems

Multiprotein transmembrane complexes in GRAM-NEGATIVE BACTERIA involved in either the secretion of effector proteins from the bacterial cytoplasm into host cells, or the secretion and assembly of flagellar components. The major component of the T3SSs is called the injectosome or needle complex.

Also Known As:

Networked: 693 relevant articles (9 outcomes, 22 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Frankel, Gad: 22 articles (02/2022 - 04/2005)
2.	Finlay, B Brett: 15 articles (01/2018 - 05/2004)
3.	Slauch, James M: 12 articles (01/2022 - 01/2004)
4.	Hartland, Elizabeth L: 11 articles (01/2021 - 04/2011)
5.	Pearson, Jaclyn S: 10 articles (01/2020 - 04/2011)
6.	Abe, Akio: 8 articles (01/2022 - 12/2003)
7.	Bäumler, Andreas J: 8 articles (12/2020 - 07/2002)
8.	Sawa, Teiji: 8 articles (01/2020 - 07/2002)
9.	Crepin, Valerie F: 8 articles (01/2017 - 12/2009)
10.	De Guzman, Roberto N: 8 articles (01/2017 - 05/2010)

Related Diseases

1.	Pneumonia (Pneumonitis) 11/01/2014 - "Using isogenic mutants in the type III secretion system, we found that the translocon, but not the effectors themselves, were required for cell-associated aggregation on the surface of polarized epithelial cells and at early time points in a murine model of acute pneumonia. " 01/01/2016 - "aeruginosa pneumonia, including its associated bacteremia and mortality, although focusing especially on type III secretion system-associated P. " 11/01/2004 - "Acute lung injury in Pseudomonas aeruginosa pneumonia depends primarily on ExoU toxin being delivered directly into the eukaryotic cell cytosol through the type III secretion system. " 04/02/2004 - "Acute lung injury in Pseudomonas aeruginosa pneumonia depends primarily on ExoU that is delivered directly into the eukaryotic cell via the type III secretion system. " 10/20/2022 - "aeruginosa type III secretion system protein, PopB, elicits a strong Th17 response in mice after intranasal (IN) immunization and confers antibody-independent protection against pneumonia in mice. "
2.	Infections 10/10/2023 - "In this study, a Gln-limited signal was found to activate the type 3 secretion system (T3SS), which is crucial for EHEC infection via perturbation of central metabolism. " 08/26/2008 - "Our studies reveal an infection paradigm whereby an extracellular pathogen uses its type III secretion system to cause at least three parallel events that eventually result in the proinflammatory death of an infected host cell." 10/31/2023 - "Here, we show that upon infection, VopY, an effector of Vibrio parahaemolyticus, is injected into host cells by type III secretion system 2 (T3SS2), a secretion system unique to its pathogenic strains and indispensable for enterotoxicity. " 06/21/2023 - "Erwinia amylovora type III secretion system inhibitors reduce fire blight infection under field conditions." 06/07/2023 - "Typhi Type 3 secretion systems (T3SSs) encoded on Salmonella Pathogenicity Islands (SPI) -1 (T3SS-1) and -2 (T3SS-2) during human macrophage infection. "
3.	Bacillary Dysentery (Shigellosis) 01/01/2021 - "An antibody targeting type III secretion system induces broad protection against Salmonella and Shigella infections." 03/05/2023 - "Enteroinvasive Escherichia coli is a prominent etiological agent of bacillary dysentery, invading via the fecal-oral route and exerting virulence on the host via the type III secretion system. " 01/01/2022 - "Shigella, the causative agent of bacillary dysentery, subvert cytoskeletal and trafficking processes to invade and replicate in epithelial cells using an arsenal of bacterial effectors translocated through a type III secretion system. " 11/01/2019 - "Using Shigella mutants lacking type III secretion systems (T3SSs), we found that T3SSs that regulate the pathogenesis of shigellosis in humans also play a central role in bacterial proliferation in Arabidopsis. " 01/01/2018 - "Shigella flexneri, an intracellular Gram-negative bacterium causative for shigellosis, employs a type III secretion system to deliver virulence effectors into host cells. "
4.	Plague (Bubonic Plague) 10/01/2019 - "The causative agent of plague, Yersinia pestis, uses a type III secretion system to selectively destroy immune cells in humans, thus enabling Y. " 09/14/2016 - "Pathogenic Yersinia, including Y. pestis, the agent of plague in humans, and Y. pseudotuberculosis, the related enteric pathogen, deliver virulence effectors into host cells via a prototypical type III secretion system to promote pathogenesis. " 09/25/2015 - "The type III secretion system (T3SS) is essential in the pathogenesis of Yersinia pestis, the causative agent of plague. " 10/01/2014 - "LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague." 12/01/2013 - "Yersinia pestis, the etiologic agent of plague, utilizes a type III secretion system (T3SS) to subvert the defenses of its mammalian hosts. "
5.	Pseudomonas Infections 03/01/2014 - "Blocking PcrV, an essential component of the Type III secretion system (TTSS), has demonstrated efficacy against Pseudomonas aeruginosa infections. " 07/01/2011 - "During infection, Pseudomonas aeruginosa uses a type III secretion system to inject a soluble AC, ExoY, into the cytosol of pulmonary microvascular endothelial cells. " 09/01/2009 - "The type III secretion system of Pseudomonas aeruginosa: infection by injection." 10/01/2003 - "Effector ExoU from the type III secretion system is an important modulator of gene expression in lung epithelial cells in response to Pseudomonas aeruginosa infection." 09/01/2014 - "Clinical outcomes of multidrug resistant pseudomonas aeruginosa infection and the relationship with type III secretion system in patients with diabetic foot."

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Vaccines
3.	Antigens
4.	Exotoxins
5.	Subunit Vaccines
6.	DNA Vaccines
7.	Antibodies
8.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
9.	Immunoglobulin G (IgG)
10.	Aerosols

Related Therapies and Procedures

1.	Therapeutics
2.	Artificial Respiration (Mechanical Ventilation)
3.	Injections
4.	Immunotherapy